ACE2 and COVID-19: Luo et al. (2020) explored the potential pharmacological effects of glycyrrhizin in COVID-19 treatment. The authors found that glycyrrhizin exerts various pharmacological effects such as angiotensin-converting enzyme II (ACE2) binding, proinflammatory cytokine downregulation, endogenous interferon induction, inhibition of intracellular R accumulation and thrombin, and excessive production of airway exudates. These findings suggest that glycyrrhizin may be a promising drug for COVID-19 treatment (Ding et al., 2020; Murck, 2020; Chrzanowski et al., 2021).